Studie biokompatibility roztoků pro peritoneální dialýzu měřená jako životaschopnost buněk v podmínkách in vitro

Stáhnout PDF English version

Autoři: Nataliia Hudz; Anna Filipska; Nataliia Stepaniuk; Nataliia Dmytrukha; Raisa Korytniuk; Piotr P. Wieczorek
Vyšlo v časopise: Čes. slov. Farm., 2019; 68, 161-172
Kategorie: Původní práce

Souhrn

Článek představuje výsledky srovnatelných testů životaschopnosti buněk HepG2 a Vero v přítomnosti tradičních roztoků pro peritoneální dialýzu (PD) provedené třemi metodami, a to pomocí (3-[4,5-dimethylthiazol]--2-yl-2,5-difenyltetrazolium bromidu (MTT), neutrální červeně (NČ) a sulforhodaminu B, se stanovením různých korelací mezi životaschopností a indexy kvality testovaných roztoků pro PD. Získané výsledky potvrdily cytotoxicitu roztoků pro PD ve srovnání s izotonickým roztokem chloridu sodného. Výsledkem působení roztoků pro PD bylo podobná redukce jak buněk HepG2, tak Vero buněk. Navíc bylo zjištěno, že metabolická buněčná aktivita je citlivější vůči působení roztoků pro PD měřených MTT testem. Dále bylo zjištěno, že míra cytotoxicity souvisí s pH roztoků a dalšími neznámými mechanismy, zatímco produkty degradace glukosy, glukosa nebo laktát nevykazovaly významný negativní účinek na cytotoxicitu roztoků pro PD. Dospělo se k závěru, že test MTT je nejvhodnější pro srovnávací studie roztoků pro PD, které se liší hodnotou jejich pH.

Klíčová slova:

roztoky pro peritoneální dialýzu – životaschopnost – HepG2 – Vero buňky – neutrální červená – MTT – sulforhodamin B

Zdroje

1. Dioos B., Paternot G., Jenvert R.-M., Duponchelle A., Marshall M. R., Nakajima M., Ganoza E. R., Sloand J. A., Wieslander A. P. Biocompatibility of a new PD solution for Japan, Reguaneal^TM, measures as in vitro proliferation of fibroblasts. Clinical and experimental nephrology 2018; https://doi.org/10.1007/s10157-018-1602-2

2. Al-Hwiesh A. K., Shawarby M. A., Abdul-Rahman I. S., Al-Oudah N., Al-Dhofairy B., Divino-Filho J. C., Abdelrahman A., Zakaria H., El-Din M. A. N., Eldamati A., El-Salamony T., Al-Muhanna F. A. Changes in peritoneal membrane with different peritoneal dialysis solutions: Is there a difference? Hong Kong Journal of Nephrology 2016; 19, 7–18; http://dx.doi.org/10.1016/j.hkjn.2016.03.001

3. Wieslander A., Linden T., Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: PD Solutions how they can be avoided. Perit. Dial. Int. 2001; 23, 119–124.

4. Schmitt C. P., Aufrich C. Is there such a thing as biocompatible peritoneal dialysis fluid? Pediatr. Nephrol. 2017; 32, 1835–1843; https://doi.org/10.1007/s00467-016-3461-y

5. Erixon M., Lindén T., Kjellstrand P., Carlsson O., Ernebrant M., Forback G. PD fluids contain high concentations of cytotoxic GDPs directly after sterilization. Peritoneal. Dial. Int. 2004; 4, 392–398.

6. Witowski J., Korybalska K., Wisniewska J., Breborowisz A., Gahl G. M., Frei U., Passlick-Deetjen J., Jorres A. Effect of glucose degradation products on human peritoneal mesothelial cell fuction. J. Am. Soc. Nephrol. 2000; 11, 729–739.

7. Cho Y., Johnson D. W., Badve S. V., Craig J. C., Strippoli G. F. M., Wiggins K. J. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney International 2013; 84, 969–979; https://doi.org/10.1038/ki.2013.190

8. Hudz N., Korytniuk R., Vyshnevska L., Wieczorek P. P. Complex technological and biological research of solutions for peritoneal dialysis, International Journal of Applied Pharmaceutics. 2018; 10(4), 59–67; https://doi.org/10.22159/ijap.2018v10i4.24823

9. Erixon M., Wieslander A., Linden Т., Carlsson O., Forsbäck G., Svensson E., Jönsson J. A., Kjellstrand P. Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs. Peritoneal Dial. Int. 2005; 25(6), 583–590.

10. Diaz-Buxo J., Sawin D.-A., Himmele R. PD solutions: new and old. Dial. Transplant. 2011; 356–361; https://doi.org/10.1002/dat.20601

11. Liao С-Т., Andrews R., Wallace L. E., Khan M. W. A., Kift-Morgan A., Topley N., Fraser D. J., Taylor P. R. Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney International 2017; 91, 1088–1103; http://dx.doi.org/10.1016/ j.kint.2016.10.030

12 Ohkuma S., Poole B. Cytoplasmic vacuolation of Mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. The Journal of Cell Biology 1981; 90(3), 656–664.

13. Angius F., Floris A. Liposomes and MTT cell viability assay: An incompatible affair. Toxicol. In Vitro 2015; 29, 314–319; https://doi.org/10.1016/j.tiv.2014.11.009

14. Gilbert D. F., Friedrich O. Cell Viability Assays: Methods and Protocols. Methods in Molecular Biology, vol. 1601; https://doi.org/10.1007/978-1-4939-6960-9_2

15. Ponsoda X., Jover R., Nunez C., Royo M., Castell J. V., Gomez-Lechon M. J. Evaluation of the cytotoxicity of 10 chemicals in human and rat hepatocytes and in cell lines: correlation between in vitro data and human lethal concentration. Toxicol. In Vitro 1995; 9(6), 959–966.

16. Test Method Protocol for the NHK Neutral Red Uptake Cytotoxicity Assay Phase III – Validation Study: November 4, 2003.

17. Keepers Y. P., Pizao P. E., Peters G. J., Ark-Otte J. V., Winograd B., Pinedo H. M. Comparison of the Sulforhodamine B Protein and Tetrazolium (MTT) Assays for in vitro Chemosensitivity Testing. Eur. J. Cancer 1991; 27(7), 897–900.

18. Perez M. G., Fourcade L., Mateescu M. A., Paguin J. Neutral Red versus MTT assay of cell viability in the presence of copper compounds.Analytical Biochemistry 2017; 535, 43–46.

19. Akter R., Uddin S. J, Tiralongo J., Grice I. D., Tiralongo E. A new cytotoxic steroidal glycoalkaloid from the methanol extract of Blumea lacera leaves. J. Pharm. Sci. 2015; 18(Suppl 4), 616–633.

20. Ammerman N. C., Beier-Sexton M., Azad A. F. Growth and Maintenance of Vero Cell Lines. Curr. Protoc Microbiol. 2008 APPENDIX: Appendix–4E; https://doi.org/10.1002/978047172 9259.mca04es11

21. Bahuguna A., Khan I., Bajpai V. K., Kang S. C. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J. Pharmacol. 2017; 2(12), 115–118; https://doi.org/10.3329/bjp.v12i2.30892

22. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols 2006; 1, 1112–1116; https://doi.org/10.1038/nprot.2006.179

23. Miller M. A., Bankier C., Al-Shaeri M., Hartl M. C. J. Neutral Red cytotoxicity assays for assessing in vivo carbon nanotube ecotoxicity in mussels – Comparing microscope and microplate methods. Marine Pollution Bulletin 2015; 101(2), 903–907; https://doi.org/10.1016/j.marpolbul.2015.10.072

24. Vajrabhaya L., Korsuwannawong S. Cytotoxicity evaluation of a Thai herb using tetrazolium (MTT) and sulforhodamine B (SRB) assays. Journal of Analytical Science and Technology 2018; 9, 15; https://doi.org/10.1186/s40543-018-0146-0

25. Kobylinska L., Patereha I., Finiuk N., Mitina N., Riabtseva A., Kotsyumbas I., Stoika R., Zaichenko A., Vari S. G. Comblike PEGcontaining polymeric composition as low toxic drug nanocarrier. Cancer Nano. 2018; 9, 1–13; https://doi.org/10.1186/s12645-018-0045-5

26. Boja P. Lysosomal Function and Dysfunction: Mechanism and Disease. Antioxidants & Redox signaling Volume 2012; 17(5), 766–774; https://doi.org/10.1089/ars.2011.4405

27. Repetto G., Peso A. D., Zurita J. L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nature Protocols 2008; 3(7), 1125–1131; https://doi.org/doi:10.1038/nprot.2008.75

28. Lim S-W.,^Loh H-S., Ting K-N., Bradshaw T. D., Allaudin Z. N. Reduction of MTT to Purple Formazan by Vitamin E Isomers in the Absence of Cells. Trop. Life Sci. Res. 2015; 26(1), 111–120.

29. Kjellstrand P., Erixon M., Wieslander A., Lindén T., Martinson E. Temperature: the single most important factor for degradation of glucose fluids during storage. Periton. Dialysis Int. 2004; 24(4), 385–391.

30. Distler L., Georgieva A., Kenkel I., Huppert J., Pischetsrieder M. Structure- and concentration-specific assessment of the physiological reactivity of α-dicarbonyl glucose degradation products in peritoneal dialysis fluids. Chem. Res. Toxicol. 2014; 27, 1421–1430; https://doi.org/10.1021/tx500153n

31. Hudz N., Kobylinska L., Dmytrukha N., Korytniuk R., Wieczorek P. P. Biological and analytical studies of peritoneal dialysis solutions. Ukr. Biochem. J. 2018; 90, 34–44; https://doi.org/10.15407/ubj90.02.034

32. British Pharmacopoeia. Edition 2009. London: The Stationery Office 2009; 10952 p.

33. Bühl A., Zöfel P. SPSS Version 10. Einführung in die modern Datenanalyse unter Windows, 7, überarbeitete und erweiterte Auflage. Diasoft: 2005; 602 p. (in Russian).

34. Stockert J. C., Blazquez-Castro A., Canete M., Horobin R. W., Villanueva A. MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochemika 2012; 14, 785–7976; https://doi.org/10.1016/j.acthis.2012.01.006

35. Perez R. P., Godwin A. K., Handel L. M. and Hamilton T. C. A comparison of Clonogenic, Microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur. J. Cancer. 1993; 3(29A), 395–399.

36. Liberek T., Topley N., Jörres A., Petersen M. M., Coles G.A., Gahl G. M., Williams J. D. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993; 65(2), 260–265; https://doi.org/ 10.1159/000187485

37. Noh H., Kim J. S., Han K-H., Lee G. T., Song J. S., Chung S. H., Jeon J. S., Ha H., Lee H. . Oxidative stress during peritoneal dialysis: Implications in functional and structural changes in the membrane. Kidney International 2006; 69, 2022–2028; https://doi.org/10.1038/sj.ki.5001506